Astellas submits enzalutamide MAA with EMA for treatment of CRPC Today, Astellas Pharma Inc. . Announces the submission of a European marketing authorisation software to the European Medicines Company for enzalutamide for the treatment of guys with metastatic castration-resistant prostate cancer who have been treated with docetaxel-based chemotherapy to become fertile http://clomid25.com .0001) in overall survival with a median improvement over placebo of 4.8 a few months [hazard ratio = 0.631]. The study also figured enzalutamide was generally well tolerated by sufferers and met all secondary endpoints.
Association between pharmaceutical outcomes and involvement in breasts cancer clinical trials Breast cancers treatment trials supported by the pharmaceutical industry are more likely to report positive results than non-sponsored research, according to a report to be posted in the April 1, 2007 problem of CANCER, a peer-reviewed journal of the American Tumor Society. Furthermore, there are significant variations in the look of trials and types of questions addressed by pharmaceutical market sponsored trials compared to non-sponsored trials. The analysis is the initial to examine the influence of the pharmaceutical industry on breast cancer analysis. Research and advancement is critical to developing new therapies.